Systemic Therapy for Stage IV Non-small Cell Lung Cancer Without Driver Alterations American Society of Clinical Oncology; Medically Reviewed by Professor Sanjay Popat May 06, 2026

https://reference.medscape.com/cc2/p10/asco-guideline-stage-iv-nsclc-without-driver-2026a10002j0?ecd=WNL_drugguide_260517_MSCPREF_onc_etid8346256&uac=148436CN&impID=8346256 Latest Guidance Updates February 2026: new and updated conditional recommendations on pembrolizumab monotherapy, nab-paclitaxel and telisotuzumab vedotin